Various factors during development can affect the efficacy of antibody-drug conjugates (ADCs), among which conjugation technology is a very important factor. A site-specific conjugation method precisely controls the conjugation site, producing a homogenous mixture, which is an especially promising path to improving ADC design.

In this study, we utilize our AGLink site-specific conjugation kit to perform site-specific enzymatic modification of IgG Fc glycans and evaluate ADC conjugation homogeneity and cytotoxicity.